Transfusion Diagnostics Market to Reach USD 4.33 Billion by 2033, Driven by Rising Blood Transfusion Procedures, Blood Safety & Advanced Screening Technologies

The global Transfusion Diagnostics Market reached US$ 2.78 billion in 2025 and is expected to reach US$ 4.33 billion by 2033, growing at a CAGR of 5.7% during 2026-2033. The market is gaining momentum with increasing demand for safe blood transfusions, infectious disease screening, blood typing, and compatibility testing. Rising awareness of transfusion safety and the need for accurate diagnostic technologies are further supporting market expansion.

The competitive landscape is increasingly focused on advanced blood screening systems, molecular diagnostics, automated testing platforms, and high-accuracy transfusion testing technologies. Technological advancements are improving the speed, reliability, and efficiency of blood screening and compatibility testing. Future growth is expected to be driven by rising blood transfusion procedures, improved screening technologies, automation, infectious disease detection, and increasing emphasis on transfusion safety, supporting steady market expansion through 2033.

Get a Sample PDF of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/transfusion-diagnostics-market?sai-v

Recent Developments

August 2026: Globally, transfusion diagnostics development increasingly focused on automated blood screening, molecular diagnostics, pathogen detection, blood-group testing, immunohematology, and digital laboratory workflows to improve transfusion safety.

July 2026: In North America, diagnostic companies continued advancing high-throughput blood screening, nucleic acid testing (NAT), automated immunohematology, and integrated laboratory systems for faster and more accurate donor and patient testing.

June 2026: In Europe, the industry increasingly emphasized advanced pathogen screening, blood-group genotyping, molecular blood typing, automation, and traceability technologies to strengthen blood safety and support complex transfusion requirements.

May 2026: In Asia-Pacific, particularly India and China, adoption of automated blood analyzers, infectious-disease screening, blood grouping systems, and molecular diagnostic technologies continued expanding alongside improvements in blood-bank infrastructure.

April 2026: The market continued shifting toward multiplex testing, AI-assisted diagnostics, automated sample processing, point-of-care testing, digital blood-bank management, and integrated transfusion information systems.

Mergers & Acquisitions
Grifols: Continued strengthening its plasma, transfusion medicine, immunohematology, blood-bank, and diagnostic solutions portfolio through strategic investments and partnerships.

Bio-Rad Laboratories: Continued expanding its immunohematology, blood typing, infectious-disease testing, molecular diagnostics, and transfusion diagnostics capabilities through product development and strategic initiatives.

Werfen: Continued advancing its transfusion technology, blood-gas testing, hemostasis, immunohematology, and diagnostic laboratory solutions, supporting integrated blood-management workflows.

Industry Consolidation: Strategic activity is increasingly centered on blood screening, molecular diagnostics, pathogen detection, blood typing, immunohematology, donor testing, infectious-disease screening, automation, AI-enabled diagnostics, and digital blood-bank management.

Key Players
Ortho Clinical Diagnostics | Beckman Coulter | Quotient Limited | Abbott Laboratories | Diagast | Becton, Dickinson & Company | Immucor Inc. | Grifols S.A. | Bio-Rad Laboratories | F. Hoffmann-La Roche Ltd. | Others

Key Highlights
Ortho Clinical Diagnostics - Holds a 14.0% share, supported by its established transfusion diagnostics portfolio, immunohematology systems, blood typing, screening, and automated laboratory solutions.

Beckman Coulter - Holds a 11.0% share, driven by its broad diagnostics portfolio, laboratory automation, immunohematology testing capabilities, and global healthcare presence.

Abbott Laboratories - Holds a 13.0% share, strengthened by its extensive diagnostics technologies, blood screening solutions, immunoassay capabilities, and global distribution network.

Grifols S.A. - Holds a 10.0% share, supported by its strong position in plasma-derived products, transfusion medicine, blood screening, and immunohematology technologies.

F. Hoffmann-La Roche Ltd. - Holds a 12.0% share, driven by its advanced diagnostics portfolio, molecular testing, blood screening technologies, and laboratory automation solutions.

Bio-Rad Laboratories - Holds an 8.0% share, supported by its immunohematology, quality-control, blood typing, and transfusion diagnostics technologies.

Becton, Dickinson & Company - Holds a 7.0% share, strengthened by its blood collection, diagnostics, laboratory technologies, and integrated solutions for transfusion medicine.

Immucor Inc. - Holds a 8.0% share, driven by its specialized immunohematology systems, blood typing, antibody screening, and transfusion testing technologies.

Quotient Limited - Holds a 6.0% share, supported by its automated blood grouping, antibody screening, and transfusion diagnostics platforms.

Diagast - Holds a 4.0% share, strengthened by its expertise in immunohematology reagents, blood-grouping technologies, and transfusion diagnostics.

Others - Hold a combined 7.0% share, comprising additional global and regional transfusion diagnostics companies competing through automated testing, molecular diagnostics, blood screening, immunohematology innovation, product launches, strategic collaborations, and laboratory automation.

Get the Full Report Here: https://www.datamintelligence.com/buy-now-page?report=transfusion-diagnostics-market?sai-v

Market Drivers
Rising demand for safe blood transfusions is increasing the adoption of advanced transfusion diagnostics for accurate blood grouping, antibody screening, crossmatching, and detection of transfusion-transmissible infections.

Growing number of blood transfusion procedures associated with surgeries, trauma care, cancer treatment, organ transplantation, and chronic diseases is supporting demand for reliable diagnostic technologies.

Increasing emphasis on preventing transfusion-related complications is encouraging hospitals and blood banks to adopt automated and highly sensitive testing platforms.

Growing adoption of molecular diagnostics and nucleic acid testing is improving the detection of infectious pathogens and supporting enhanced blood-safety screening.

Increasing automation of blood banks and transfusion laboratories is driving demand for high-throughput analyzers, automated blood grouping systems, and integrated diagnostic workflows.

Growing investments in healthcare infrastructure, blood-bank modernization, and advanced laboratory technologies are creating opportunities for transfusion diagnostics providers.

Industry Developments
Increasing adoption of automated blood grouping, antibody screening, and crossmatching systems to improve laboratory efficiency and reduce manual errors.

Growing integration of molecular diagnostics and nucleic acid testing for more sensitive detection of transfusion-transmissible infections.

Increasing development of multiplex diagnostic platforms capable of performing multiple blood-grouping, compatibility, and infectious-disease tests within integrated workflows.

Growing adoption of artificial intelligence, digital laboratory systems, and data-management technologies for improving transfusion laboratory operations and traceability.

Increasing development of point-of-care and rapid testing technologies to accelerate blood compatibility assessment and improve decision-making in urgent transfusion settings.

Strategic collaborations, acquisitions, product launches, and technology investments among diagnostic companies, blood-bank technology providers, and healthcare organizations are strengthening the competitive landscape.

Regional Insights
North America - 39.20% share: "Led the global transfusion diagnostics market in 2025, supported by advanced healthcare infrastructure, established blood-bank networks, high adoption of automated diagnostic systems, stringent blood-safety standards, and strong investments in laboratory technologies."

Europe - 29.10% share: "Supported by well-established blood-transfusion systems, stringent regulatory requirements, advanced laboratory infrastructure, and increasing adoption of automated and molecular transfusion diagnostic technologies."

Asia Pacific - 23.40% share: "Driven by expanding healthcare infrastructure, increasing blood-transfusion requirements, growing investments in blood-bank modernization, rising healthcare expenditure, and increasing adoption of automated diagnostic platforms."

Latin America - 4.90% share: "Supported by improving blood-bank infrastructure, increasing healthcare investments, greater awareness of transfusion safety, and gradual adoption of advanced blood-grouping and infectious-disease testing technologies."

Middle East & Africa - 3.40% share: "Driven by healthcare modernization, expansion of blood-transfusion services, increasing investments in laboratory infrastructure, and growing efforts to improve blood safety and diagnostic capabilities."

Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/transfusion-diagnostics-market?sai-v

Key Segments
➥ By Type

Instruments & Kits: Represents the dominant segment, driven by increasing demand for automated blood testing systems, diagnostic kits, blood typing equipment, and advanced transfusion testing technologies.

Reagents: Represents a significant and rapidly growing segment, supported by continuous demand for blood grouping, compatibility testing, disease screening, and other routine transfusion diagnostic procedures.

Others: Represents a growing segment, fueled by adoption of consumables, software, accessories, and supporting products used across transfusion diagnostic workflows.

➥ By Application

Blood Grouping: Represents the dominant segment, driven by the essential requirement for accurate ABO and Rh blood typing, increasing blood transfusion volumes, and growing adoption of automated blood grouping technologies.

Disease Screening: Represents a significant and rapidly growing segment, supported by increasing emphasis on blood safety, screening for transfusion-transmissible infections, regulatory requirements, and advanced diagnostic technologies.

Others: Represents an expanding segment, driven by increasing adoption of compatibility testing, antibody screening, crossmatching, and other specialized transfusion diagnostic procedures.

➥ By End User

Hospitals: Represents the dominant segment, driven by high volumes of blood transfusions, availability of advanced diagnostic infrastructure, emergency care requirements, and increasing demand for accurate pre-transfusion testing.

Laboratories: Represents a significant segment, supported by increasing outsourcing of diagnostic testing, growing testing volumes, specialized laboratory capabilities, and adoption of automated transfusion diagnostic systems.

Blood Banks: Represents a dominant and important segment, fueled by the critical need for blood grouping, donor screening, compatibility testing, infectious disease screening, and quality assurance throughout the blood supply process.

Plasma Fractionation Facilities: Represents a growing segment, driven by increasing demand for plasma-derived products, stringent quality and safety requirements, and the need for reliable screening and testing of plasma collections.

Others: Represents an expanding segment, supported by adoption of transfusion diagnostic technologies across diagnostic centers, research institutions, specialty healthcare facilities, and other blood-management settings.

Explore the report here: https://www.datamintelligence.com/research-report/transfusion-diagnostics-market

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.